15,000 Shares in Bright Minds Biosciences Inc. (NASDAQ:DRUG) Acquired by Atika Capital Management LLC

Atika Capital Management LLC acquired a new stake in Bright Minds Biosciences Inc. (NASDAQ:DRUG) in the 4th quarter, Holdings Channel.com reports. The fund acquired 15,000 shares of the company’s stock, valued at approximately $540,000.

Bright Minds Biosciences Stock Down 3.3 %

Bright Minds Biosciences stock opened at $32.04 on Friday. The stock has a market cap of $225.69 million, a PE ratio of -188.46 and a beta of -5.50. Bright Minds Biosciences Inc. has a 12-month low of $0.93 and a 12-month high of $79.02. The business’s 50-day moving average price is $36.38 and its two-hundred day moving average price is $33.77.

Bright Minds Biosciences (NASDAQ:DRUG) last released its quarterly earnings data on Thursday, February 13th. The company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.24. As a group, analysts expect that Bright Minds Biosciences Inc. will post -1.24 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently commented on DRUG. HC Wainwright restated a “buy” rating and issued a $85.00 price target on shares of Bright Minds Biosciences in a research report on Wednesday, February 19th. Cantor Fitzgerald started coverage on shares of Bright Minds Biosciences in a research report on Friday, January 10th. They issued an “overweight” rating for the company. Finally, Piper Sandler initiated coverage on shares of Bright Minds Biosciences in a research note on Thursday, January 23rd. They issued an “overweight” rating and a $93.00 price objective on the stock. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $84.33.

Bright Minds Biosciences Company Profile

Bright Minds Biosciences Inc, a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder.